Is Theravance Biopharma Inc (TBPH) overvalued? · P/E 7.5, rev $18.8M
Theravance Biopharma Inc (TBPH) is a biotechnology company listed on NASDAQ.
This page asks whether Theravance Biopharma Inc (TBPH) looks expensive on cached numbers — not a short thesis.
Latest reported TBPH revenue for 2024-12-31 was $18.8M. Net income was -$15.5M. Revenue was up 11.2% from 2024-09-30 to 2024-12-31. TBPH currently screens at market cap $861.5M and trailing P/E 7.5.
TBPH currently screens at market cap $861.5M and trailing P/E 7.5. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next TBPH 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the TBPH stock page for the full model, not this heading.
Not investment advice.